During the 24th Congress of the European Rhinologic Society, in conjunction with the 31st International Symposium on Infection and Allergy of the Nose, which took place in Toulouse last June, the European Position Paper on Rhinosinusitis and Nasal Polyps 2012 was presented. Four of the leaders of this project, gave a talk on the key aspects of the document, which is intended to be a state-of-the art review for the specialist and general practitioner alike.

To agree the final version, leaders in the field of ENT were invited to critically appraise the literature and write a report on a subject assigned to them. All contributions were distributed before
a meeting in November, when the group came together in Amsterdam. 4 days of the meeting were dedicated to discussing every report in detail. In addition, general discussions on important dilemmas and controversies took place. Finally, the management schemes were revised significantly, in light of new data that was available.

In view of said data, Cyclamen europaeum (Nasodren active substance) has been included in EPOS 2012 with highest level of evidence Ib and maximum level of recommendation A. This means that the efficacy and safety of Nasodren is endorsed by the most important paper in the ENT world and, consequently, should not be questioned.